Lutetium 177 rosopatamab tetraxetan - Telix Pharmaceuticals
Alternative Names: 177-Lu-DOTA-Rosopatamab - Telix Pharmaceuticals; 177Lu-DOTA-rosopatamab; 177Lu-DOTA-rosopatamb; 177Lu-DOTA-TLX591; 177Lu-DOTA-TLX591-CHO; 177Lu-TLX-591; Lutetium 177 DOTA rosopatamab - Telix Pharmaceuticals; Lutetium 177 rosopatamab - Telix Pharmaceuticals; TLX 591; TLX591t; TX591Latest Information Update: 27 Aug 2024
At a glance
- Originator Telix Pharmaceuticals
- Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Prostate cancer
Most Recent Events
- 22 Aug 2024 Phase-III clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04876651)
- 22 Aug 2024 US FDA approves IND application for Lutetium 177 rosopatamab tetraxetan for phase III ProstACT-GLOBAL trial in Prostate cancer
- 31 Jul 2024 Telix Pharmaceuticals plans phase III ProstACT-GLOBAL trial in Prostate cancer (Metastatic disease, Hormone refractory, Second-line therapy or greater, Combination therapy) (IV) (NCT06520345)